AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23134272
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy and guided visual imagery
Trial: 16675324
Drug: Beta-agonist asthma
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-agonist asthma control scale derived from administrative data
Trial: 16675324
Drug: Beta-agonist asthma
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-agonist asthma control scale
Trial: 15327427
Drug: SSFP without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SSFP without magnetization preparation
Trial: 10903238
Drug: Continuous group
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous group (maintenance prednisone dose for 6 months)
Trial: 10903238
Drug: Demand group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demand group (withdrawn from prednisone at a rate of 5 mg per week)
Trial: 8161669
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg/day for 7 days
Trial: 3531309
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg twice daily (b.i.d.)
Trial: 22698700
Drug: 400 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 μg of misoprostol
Trial: 19833454
Drug: sublingual 200microg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sublingual 200microg misoprostol with 20UI intravenous oxytocin
Trial: 19833454
Drug: only oxytocin
RxNorm normalized name: Product containing only oxytocin (medicinal product)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: only oxytocin at the same dose
Trial: 16706761
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (Fucidine cream with Cutiplast sterile dressing)
Trial: 11305006
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (5 g administered for 3 days)
Trial: 326237
Drug: 3% vancomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% vancomycin gel applied topically using pre-trimmed plastic trays for 5 minutes every morning in school.
Trial: 326237
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no vancomycin treatment).
Trial: 24372884
Drug: Explicit speech
RxNorm normalized name: Empliciti
DrugBank: Elotuzumab (DB06317)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Explicit speech and language therapy with visual support (Shape Coding)
Trial: 24372884
Drug: Waiting controls
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting controls (no therapy during Phase 1)
Trial: 24372884
Drug: Waiting controls
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting controls (after receiving therapy in Phase 2)
Trial: 24372884
Drug: Combined groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined groups (therapy and waiting controls)
Trial: 20134096
Drug: Shock wave
RxNorm normalized name: ELECTRODE GEL,H-WAVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shock wave (SW) therapy
Trial: 18391039
Drug: Entecavir 1
RxNorm normalized name: entecavir 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entecavir 1 mg daily dose in HIV- and HBV-coinfected patients
Trial: 18391039
Drug: Entecavir 1
RxNorm normalized name: entecavir 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entecavir 1 mg daily dose in HBV-monoinfected patients
Trial: 18391039
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of entecavir pharmacokinetics between HIV- and HBV-coinfected and HBV-monoinfected patients
Trial: 12520628
Drug: Norethindrone acetate/ethinyl
RxNorm normalized name: norethindrone acetate/ethinyl estradiol 1 mg-5 mcg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norethindrone acetate/ethinyl estradiol tablets administered with a high-fat meal
Trial: 12520628
Drug: Norethindrone acetate/ethinyl
RxNorm normalized name: norethindrone acetate/ethinyl estradiol 1 mg-5 mcg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norethindrone acetate/ethinyl estradiol tablets administered fasting
Trial: 12520628
Drug: Norethindrone acetate/ethinyl
RxNorm normalized name: norethindrone acetate/ethinyl estradiol 1 mg-5 mcg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norethindrone acetate/ethinyl estradiol tablets administered in solution
Trial: 9433680
Drug: Vitamins (beta‐carotene,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamins (beta‐carotene, 6 mg; vitamin C, 120 mg; and vitamin E, 15 mg)
Trial: 9433680
Drug: Trace elements
RxNorm normalized name: trace elements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trace elements (zinc, 20 mg and selenium, 100 micrograms)
Trial: 8270292
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg on alternate days
Trial: 8270292
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg (single dose)
Trial: 3304837
Drug: Ranitidine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 200 mg/day iv
Trial: 3304837
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg/day iv
Trial: 24682207
Drug: Caffeine (2.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (2.9 mg/kg, equivalent to 200 mg or 2 espressos for a 70-kg adult)
Trial: 18177726
Drug: Taranabant (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taranabant (0.5, 2, 4, and 6 mg once per day)
Trial: 16188812
Drug: Surfactant (Curosurf)
RxNorm normalized name: Curosurf
DrugBank: Poractant alfa (DB09113)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Surfactant (Curosurf) at 200 mg/kg, repeated doses of 200, 100, and 100 mg/kg at 6-12 h intervals, maximum of four doses if OI deteriorated by >2 from baseline
Trial: 8888089
Drug: Adalat CC
RxNorm normalized name: Adalat CC
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adalat CC
Trial: 27487342
Drug: PTH‐1‐37 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTH‐1‐37 (10 µg, 20 µg, 40 µg)
Trial: 27487342
Drug: PTH‐1‐34 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTH‐1‐34 (20 µg)
Trial: 1725153
Drug: 400mg aqueous
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg aqueous solution
Trial: 1725153
Drug: 400mg tablet
RxNorm normalized name: IBU 400mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg tablet
Trial: 1725153
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 200mg tablets
Trial: 6178151
Drug: Hapten (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hapten (10 or 20 ml) before dextran infusion
Trial: 30885996
Drug: Imatinib 400
RxNorm normalized name: imatinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 400 mg
Trial: 30885996
Drug: Imatinib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 800 mg
Trial: 31813633
Drug: Obeticholic acid
RxNorm normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Obeticholic acid 10 mg
Trial: 25418218
Drug: Human recombinant
RxNorm normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human recombinant BNP (rhBNP; 0.005 μg/kg/min)
Trial: 25418218
Drug: Isotonic normal
RxNorm normalized name: ISOTON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic normal saline (NaCl 0.9%, 1 mL/kg/h) for 24 hours before CA or PCI
Trial: 20635771
Drug: Cognitive Behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavior Therapy (CBT) for Panic Disorder
Trial: 18192953
Drug: Natriuretic peptides
RxNorm normalized name: Natriuretic peptides b
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natriuretic peptides (NPs) applied prophylactically, in lower doses, for prolonged duration.
Trial: 2913779
Drug: Prazosin, Propranolol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin, Propranolol, Hydrochlorothiazide (all drug treatment groups)
Trial: 22334770
Drug: All active
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All active treatment groups
Trial: 64267
Drug: gestonorone caproate
RxNorm normalized name: Gestonorone caproate
DrugBank: Gestonorone caproate (DB14677)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gestonorone caproate (200 mg daily and 200 mg on alternate days)
Trial: 64267
Drug: cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyproterone acetate (300 mg daily)
Trial: 31952493
Drug: Active TDM
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active TDM (therapeutic drug monitoring) of beta-lactam and fluoroquinolones
Trial: 26350273
Drug: Paroxetine 20
RxNorm normalized name: PARoxetine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20 mg once daily for 12 days
Trial: 26350273
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 12 days
Trial: 10708180
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 mL of sterile water)
Trial: 30012385
Drug: Flavonols (63.36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavonols (63.36 mg/d)
Trial: 30012385
Drug: Flavanols (107.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavanols (107.61 mg/d)
Trial: 30012385
Drug: Flavanones (40.92
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavanones (40.92 mg/d)
Trial: 30012385
Drug: Catechins (63.36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catechins (63.36 mg/d)
Trial: 26970526
Drug: Tofacitinib XR
RxNorm normalized name: tofacitinib Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib XR 11 mg QD
Trial: 26970526
Drug: Tofacitinib IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib IR 5 mg twice daily
Trial: 26970526
Drug: Tofacitinib XR
RxNorm normalized name: tofacitinib Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib XR 11 mg QD (fed state)
Trial: 26970526
Drug: Tofacitinib XR
RxNorm normalized name: tofacitinib Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib XR 11 mg QD (multiple doses)
Trial: 26970526
Drug: Tofacitinib IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib IR 5 mg twice daily (multiple doses)
Trial: 21935685
Drug: Intravenous dezocine
RxNorm normalized name: DEZOCINE
DrugBank: Dezocine (DB01209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous dezocine 0.1 mg/kg
Trial: 20194448
Drug: Rituximab retreatment
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab retreatment (2 x 1000 mg IV)
Trial: 12740233
Drug: Hydrocortisone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (200 to 300 mg/d) for 1 to 3 weeks
Trial: 1624634
Drug: h-EGF (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: h-EGF (10 micrograms/mL, applied topically twice a day for up to 10 weeks)
Trial: 1624634
Drug: Placebo (applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (applied topically twice a day for up to 10 weeks)
Trial: 6334524
Drug: 1,25-dihydroxyvitamin D
RxNorm normalized name: 1,25-dihydroxyvitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,25-dihydroxyvitamin D (mean dose 0.4 micrograms/day)
Trial: 29372470
Drug: Topiroxostat (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiroxostat (40 to 160 mg/day, administered BID for 28 weeks)
Trial: 29372470
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching placebo administered BID for 28 weeks)
Trial: 27863179
Drug: Bedaquiline (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedaquiline (24 weeks treatment)
Trial: 25358679
Drug: Antenatal milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antenatal milk expressing starting at 36 weeks gestation, encouraged to express twice daily for 10 min.
Trial: 19227901
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg/day for 3 months
Trial: 19227901
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no inhibitors of GMG-CoA-reductase)
Trial: 15895898
Drug: SINGLE therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SINGLE therapy (initially sulfasalazine with or without prednisolone)
Trial: 15895898
Drug: COMBI therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COMBI therapy (sulfasalazine, methotrexate, hydroxychloroquine, and prednisolone)
Trial: 15895898
Drug: sIL‐2R <442
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sIL‐2R <442 U/ml
Trial: 2105673
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg naltrexone
Trial: 2205128
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg naltrexone
Trial: 23727387
Drug: Apomorphine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine (1.5 mg)
Trial: 21820539
Drug: Weekly musculoskeletal
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly musculoskeletal treatment for 6 weeks in addition to normal optimal physiotherapy care
Trial: 11573528
Drug: Ketoprofen 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 0.5 mg kg(‐1) at induction followed by continuous infusion of 3 mg kg(‐1) over 24 h (pre ketoprofen group)
Trial: 11573528
Drug: Ketoprofen 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 0.5 mg kg(‐1) after surgery followed by continuous infusion of 3 mg kg(‐1) over 24 h (post ketoprofen group)
Trial: 9661740
Drug: 400 mg/day
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/day of carbamazepine (CBZ)
Trial: 9661740
Drug: 800 mg/day
RxNorm normalized name: RibaTab 800 mg/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg/day of valproic acid (VPA)
Trial: 9661740
Drug: 400 mg/day
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/day of carbamazepine (CBZ) and 800 mg/day of valproic acid (VPA)
Trial: 8151854
Drug: Steam treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steam treatment (40 L/min of heated saturated air at 43 degrees C for 60 minutes)
Trial: 8151854
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (2 L/min of ambient air at 20 degrees C to 24 degrees C)
Trial: 3219316
Drug: 0.3 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 g/kg body-weight per day
Trial: 3219316
Drug: 0.45 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.45 g/kg body-weight per day
Trial: 3219316
Drug: 0.6 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 g/kg body-weight per day
Trial: 3219316
Drug: 0.75 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 g/kg body-weight per day
Trial: 28840615
Drug: Phospholipidated Curcumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phospholipidated Curcumin (1 g/day, containing 200 mg of pure curcumin)
Trial: 28840615
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 g/day)
Trial: 26057939
Drug: Aspirin supplementation
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin supplementation (acute and chronic)
Trial: 23937271
Drug: Dapoxetine 30
RxNorm normalized name: duloxetine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapoxetine 30 mg plus mirodenafil 50 mg (group B)
Trial: 23937271
Drug: Dapoxetine 30
RxNorm normalized name: duloxetine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapoxetine 30 mg plus placebo (group A)
Trial: 21803422
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg linagliptin after an overnight fast of at least 10 hours
Trial: 21803422
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg linagliptin after ingestion of a high-fat, high-calorie breakfast
Trial: 19781210
Drug: Atorvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (20 mg/qn)
Trial: 12932070
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no atorvastatin)
Trial: 24625934
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium 100 mg
Trial: 9576201
Drug: alpha2b-IFN (Intron-A)
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha2b-IFN (Intron-A) maintenance therapy
Trial: 9576201
Drug: no maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no maintenance therapy
Trial: 7936018
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of azathioprine
Trial: 2953770
Drug: Intravenous tissue
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tissue plasminogen activator (1.25 mg/kg body weight over 3 hours)
Trial: 20932130
Drug: Er:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er:YAG laser therapy (2,940 nm, 60 mJ/pulse, 2 Hz, 20 s)
Trial: 20932130
Drug: Nd:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nd:YAG laser therapy (1,064 nm, 100 mJ/pulse, 15 Hz, 100 s)
Trial: 20932130
Drug: Diode laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diode laser therapy (808 nm, 100 mW, 20s)
Trial: 18823688
Drug: Daily hemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily hemodialysis (DHD)
Trial: 12271300
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream applied 3 times per week for 8 weeks
Trial: 12271300
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream applied to the other side of the body
Trial: 9649912
Drug: Enalapril 10-40
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10-40 mg o.d. after 3 and 12 months
Trial: 7530029
Drug: bovine heparin
RxNorm normalized name: BOVINE HEPARIN
DrugBank: Heparin, bovine (DB15404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bovine heparin 300 u. kg‐1 (standard)
Trial: 7530029
Drug: heparin 300
RxNorm normalized name: TAUROLIDINE 40.5 mg in 3 mL / HEPARIN 3000 [USP'U] in 3 mL INTRALUMINAL SOLUTION [DEFENCATH]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: heparin 300 u. kg‐1 followed by a continuous infusion of 10,000 u. kg‐1 until the end of CPB
Trial: 7530029
Drug: heparin 600
RxNorm normalized name: Heparine
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: heparin 600 u. kg‐1
Trial: 7530029
Drug: heparin 600
RxNorm normalized name: Heparine
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: heparin 600 u. kg‐1 in addition to high‐dose aprotinin 2 million iu before CPB, 500,000 iu h‐1 until the end of operation and 2 million iu added to the prime
Trial: 1952132
Drug: saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: saline solution (control)
Trial: 1632701
Drug: Oral OK-432
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral OK-432
Trial: 2586435
Drug: Intravenous OK-432
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous OK-432
Trial: 781905
Drug: Busulphan (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Busulphan (mean dosage of 464 mg over 301 days)
Trial: 31752850
Drug: Pitavastatin 1
RxNorm normalized name: PITAVASTATIN 1MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin 1 mg
Trial: 23556337
Drug: Non-G carriers
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-G carriers of ABCB1 G2677T/A